Leadership of a national sales division responsible for selling pharmaceuticals and medical supplies via phone and web based application to physicians, clinics and hospitals. Transformed the division from a call center to sales center.> 2021-Doubled division operating profit vs. last year.> 2021-Created organizational career ladders for sales representatives and managers.> 2020-Optimized division headcount during a pandemic.Cost savings ~$500K.> 2019 to present. Reduced division freight expenses. Cost savings ~$400K> 2019 Reduced account credit card charges $8M to improve the bottom line. Cost savings ~$160K> 2018 Recaptured $30M of top line sales after loss of a top selling brand item.> Designed a division scorecard to improve KPI performance.

Promoted to lead a National Inside Sales team supporting and distributing Pharmaceuticals. Product business segments include Trelstar- Urology/Oncology, Prolia - Rheumatology, Oral Contraceptives, IUD's and HIV testing for Planned Parenthood.

Leadership of an inside selling team of 12 representatives for a national distributor of pharmaceutical products. Responsible for delivering organizational sales results and providing superior customer service to physician practices across the Midwestern U.S. (16 states). Coach, mentor and train employees on products, sales methods and achieving sales objectives.Identify and address representative's skill gaps,create action plans to achieve goals. Current portfolio includes vaccines, injectables, med/surgical supplies, oral medications and equipment

Built a distinguished career of achievement and advancement that included promotion to District Manager in 2006; after moving from entry-level to Executive Sales Consultant. Recruited, hired and coached teams of up to 12 representatives, responsible for increasing sales in South Florida. Designed and executed strategies and programs to support goal achievement through periods of constantly changing organizational structure and dynamic market shifts; with wide array of products in both primary care and specialty arenas. Key Accomplishments:• Sales Leadership–Used performance management to improve region rank from 7/7 to 2/7 first year to earn District Manager of the Year, Top Growth District and Impact Award. Drove sales performance for a $4M Reclast district using buy and bill strategies. Surpassed regional and operating unit growth trends; increased sales 77% and 27% over prior years in 2009 and 2010. Ranked 9th/512 in the nation for volume and revenue generated.Recognized in national publication as an influential mentor by a direct report;• Product Launches–Developed and implemented plans that resulted in top performance launch of several new products, including Exelon Patch, Tekturna and Exforge. Ranked #1 or 2 for volume and market share generated for each launch product 2007 and 2008. • New Market Penetration–Infiltrated new market segments of Long Term Care and Neuroscience with Exelon Patch; improved district’s ranking by 7 places, to the top 21% - 2009.• Strategy & Implementation Plans— Used Culture and Professional Associations as a platform to create meaningful Thought Leader Speaker Programs.

Sold cardiovascular, gastrointestinal and osteoporosis products to Rheumatologists, Cardiologists, Gastroenterologists, Nephrologists, Neurologists and Primary Care physicians in Broward, Dade, Palm Beach counties, FL. Assumed district leadership responsibilities such as, training new field sales representatives, leading team meetings, managing team budgets and performing data analyses. Consistently grew both mature and new products throughout sales career; marketed Diovan/HCT, Exelon Patch, Famvir, Lotrel, Miacalcin, and Zelnorm. Sales Key Accomplishments:• Ranked in (Top 2%) in nation during period from April 2000 to December 2003. • Ranked (11/512) in nation overall; exceeded all three product goals; with 146+% of goal in 2003. • Won District MVP Award for outstanding sales results in 2002; delivered 118+% of total portfolio goal. • Finished 2001 ranked (2/12) in district and (30/86) in nation for primary product Famvir; achieved 105% of overall goal.